
Chien-Wei Su

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9043344/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. Journal of Hepatology, 2009, 51, 890-897.	3.7	369
2	Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology, 2009, 50, 1464-1474.	7.3	321
3	Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B—A Nationwide Cohort Study. Gastroenterology, 2014, 147, 143-151.e5.	1.3	267
4	Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. Journal of Hepatology, 2016, 64, 601-608.	3.7	220
5	Genotypes and Viremia of Hepatitis B and D Viruses Are Associated With Outcomes of Chronic Hepatitis D Patients. Gastroenterology, 2006, 130, 1625-1635.	1.3	193
6	Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology, 2013, 57, 112-119.	7.3	168
7	Delayed endoscopy increases re-bleeding and mortality in patients with hematemesis and active esophageal variceal bleeding: A cohort study. Journal of Hepatology, 2012, 57, 1207-1213.	3.7	166
8	A new prognostic model for hepatocellular carcinoma based on total tumor volume: The Taipei Integrated Scoring system. Journal of Hepatology, 2010, 53, 108-117.	3.7	157
9	Survival Rates Are Comparable After Radiofrequency Ablation or Surgery in Patients With Small Hepatocellular Carcinomas. Clinical Gastroenterology and Hepatology, 2011, 9, 79-86.	4.4	151
10	Comparison of Surgical Resection and Transarterial Chemoembolization for Hepatocellular Carcinoma beyond the Milan Criteria: A Propensity Score Analysis. Annals of Surgical Oncology, 2012, 19, 842-849.	1.5	108
11	External Validation of Fatty Liver Index for Identifying Ultrasonographic Fatty Liver in a Large-Scale Cross-Sectional Study in Taiwan. PLoS ONE, 2015, 10, e0120443.	2.5	105
12	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. Journal of the Formosan Medical Association, 2018, 117, 381-403.	1.7	92
13	Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon-α-2A Therapy. Antiviral Therapy, 2011, 16, 629-637.	1.0	91
14	Hepatic resection can provide long-term survival of patients with non–early-stage hepatocellular carcinoma: Extending the Indication for resection?. Surgery, 2012, 152, 809-820.	1.9	90
15	Selecting an optimal staging system for hepatocellular carcinoma. Cancer, 2010, 116, 3006-3014.	4.1	88
16	Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation. Radiology, 2017, 285, 670-680.	7.3	88
17	A Comparison of Prognosis between Patients with Hepatitis B and C Virusâ€related Hepatocellular Carcinoma Undergoing Resection Surgery. World Journal of Surgery, 2011, 35, 858-867.	1.6	87
18	Inverse Association between Hepatitis B Virus Infection and Fatty Liver Disease: A Large-Scale Study in Populations Seeking for Check-Up. PLoS ONE, 2013, 8, e72049.	2.5	76

#	Article	IF	CITATIONS
19	Vascular Invasion in Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2014, 48, 734-741.	2.2	68
20	The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy. PLoS ONE, 2013, 8, e66457.	2.5	67
21	Outcome After Percutaneous Cholecystostomy for Acute Cholecystitis: a Single-Center Experience. Journal of Gastrointestinal Surgery, 2012, 16, 1860-1868.	1.7	66
22	Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: A propensity score analysis. Liver Transplantation, 2011, 17, 556-566.	2.4	63
23	Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. Hepatology, 2015, 61, 1870-1879.	7.3	63
24	Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatology International, 2010, 4, 691-699.	4.2	60
25	The Effect of Age on the Long-term Prognosis of Patients With Hepatocellular Carcinoma After Resection Surgery. Archives of Surgery, 2012, 147, 137.	2.2	60
26	A new ALBIâ€based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver International, 2019, 39, 1704-1712.	3.9	58
27	Younger Hepatocellular Carcinoma Patients Have Better Prognosis After Percutaneous Radiofrequency Ablation Therapy. Journal of Clinical Gastroenterology, 2012, 46, 62-70.	2.2	56
28	Hepatitis B Surface Antigen Levels and Sequences of Natural Hepatitis B Virus Variants Influence the Assembly and Secretion of Hepatitis D Virus. Journal of Virology, 2008, 82, 2250-2264.	3.4	55
29	Updated thresholds for serum alanine aminotransferase level in a largeâ€scale population study composed of 34Â346 subjects. Alimentary Pharmacology and Therapeutics, 2012, 36, 560-568.	3.7	55
30	Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy. European Journal of Gastroenterology and Hepatology, 2011, 23, 1.	1.6	53
31	Risk of oral antifungal agentâ€induced liver injury in <scp>T</scp> aiwanese. British Journal of Clinical Pharmacology, 2014, 77, 180-189.	2.4	51
32	Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. Annals of Surgical Oncology, 2016, 23, 874-883.	1.5	51
33	Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. International Journal of Cancer, 2013, 133, 2895-2902.	5.1	49
34	Forfeited hepatogenesis program and increased embryonic stem cell traits in young hepatocellular carcinoma (HCC) comparing to elderly HCC. BMC Genomics, 2013, 14, 736.	2.8	45
35	Cancer risk in patients with pyogenic liver abscess: a nationwide cohort study. Alimentary Pharmacology and Therapeutics, 2012, 36, 467-476.	3.7	43
36	Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. Clinical Radiology, 2012, 67, 429-436.	1.1	42

#	Article	IF	CITATIONS
37	Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. European Journal of Cancer, 2016, 63, 25-33.	2.8	40
38	Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. European Journal of Surgical Oncology, 2019, 45, 776-781.	1.0	38
39	Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigenâ€negative chronic hepatitis B patients in Taiwan. Journal of Viral Hepatitis, 2003, 10, 277-284.	2.0	37
40	Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Scientific Reports, 2016, 6, 29605.	3.3	37
41	Validation of the albuminâ€bilirubin gradeâ€based integrated model as a predictor for sorafenibâ€failed hepatocellular carcinoma. Liver International, 2018, 38, 321-330.	3.9	37
42	Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. PLoS ONE, 2016, 11, e0155588.	2.5	37
43	Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy. Hepatology International, 2013, 7, 188-198.	4.2	36
44	Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. Digestive and Liver Disease, 2010, 42, 137-142.	0.9	35
45	Validation of the HCCâ€MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy. Clinical Transplantation, 2008, 22, 469-475.	1.6	34
46	Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver International, 2010, 30, 77-84.	3.9	34
47	Same-day Versus Split-dose Bowel Preparation Before Colonoscopy. Journal of Clinical Gastroenterology, 2018, 52, 392-400.	2.2	34
48	Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. BMC Gastroenterology, 2010, 10, 146.	2.0	33
49	Radiofrequency Ablation is Better Than Surgical Resection in Patients With Hepatocellular Carcinoma Within the Milan Criteria and Preserved Liver Function. Journal of Clinical Gastroenterology, 2015, 49, 242-249.	2.2	33
50	Prognosis of Early-Stage Hepatocellular Carcinoma. Medicine (United States), 2015, 94, e1929.	1.0	32
51	Impact of Steatosis on Prognosis of Patients with Early-Stage Hepatocellular Carcinoma After Hepatic Resection. Annals of Surgical Oncology, 2015, 22, 2253-2261.	1.5	31
52	Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice. Medicine (United States), 2015, 94, e688.	1.0	30
53	Combination of albumin-bilirubin grade and platelets to predict a compensated patient with hepatocellular carcinomaÂwho does not require endoscopic screening for esophageal varices. Gastrointestinal Endoscopy, 2018, 88, 230-239.e2.	1.0	30
54	Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Renal Insufficiency. Journal of Clinical Gastroenterology, 2010, 44, e171-e177.	2.2	29

#	Article	IF	CITATIONS
55	Comparative Analysis of Noninvasive Models to Predict Early Liver Fibrosis in Hepatitis B e Antigen-negative Chronic Hepatitis B. Journal of Clinical Gastroenterology, 2011, 45, 278-285.	2.2	28
56	Milan Criteria, Multi-nodularity, and Microvascular Invasion Predict the Recurrence Patterns of Hepatocellular Carcinoma After Resection. Journal of Gastrointestinal Surgery, 2013, 17, 702-711.	1.7	28
57	Application of serologic assays for diagnosing acute hepatitis E in national surveillance of a nonendemic area. Journal of Medical Virology, 2014, 86, 720-728.	5.0	28
58	Albuminâ€bilirubin gradeâ€based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma. Liver International, 2020, 40, 205-214.	3.9	28
59	The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. Liver Cancer, 2018, 7, 335-358.	7.7	27
60	Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development. Hepatology, 2021, 74, 641-655.	7.3	27
61	When to Perform Surgical Resection or Radiofrequency Ablation for Early Hepatocellular Carcinoma?. Medicine (United States), 2015, 94, e1808.	1.0	26
62	Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Scientific Reports, 2018, 8, 4773.	3.3	26
63	IL28B Polymorphism Correlates with Active Hepatitis in Patients with HBeAg-Negative Chronic Hepatitis B. PLoS ONE, 2013, 8, e58071.	2.5	26
64	Association of core promoter/precore mutations and viral load in e antigen-negative chronic hepatitis B patients. Journal of Viral Hepatitis, 2006, 13, 336-342.	2.0	25
65	Predictive Value of Aspartate Aminotransferase to Alanine Aminotransferase Ratio for Hepatic Fibrosis and Clinical Adverse Outcomes in Patients With Primary Biliary Cirrhosis. Journal of Clinical Gastroenterology, 2009, 43, 876-883.	2.2	25
66	Surgical resection <i>versus</i> transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. Journal of Surgical Oncology, 2015, 111, 404-409.	1.7	25
67	The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. Scientific Reports, 2017, 7, 42577.	3.3	25
68	Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Scientific Reports, 2018, 8, 843.	3.3	25
69	Lymphoid Enhancer Factor 1 Contributes to Hepatocellular Carcinoma Progression Through Transcriptional Regulation of Epithelialâ€Mesenchymal Transition Regulators and Stemness Genes. Hepatology Communications, 2018, 2, 1392-1407.	4.3	25
70	Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis. Journal of the Chinese Medical Association, 2017, 80, 125-132.	1.4	24
71	Natural history and prognostic factors of primary biliary cirrhosis in Taiwan: a followâ€up study up to 18 years. Liver International, 2008, 28, 1305-1313.	3.9	23
72	α-Fetoprotein-to-Total Tumor Volume Ratio Predicts Post-operative Tumor Recurrence in Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2013, 17, 730-738.	1.7	23

#	Article	IF	CITATIONS
73	Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. Hepatology, 2019, 69, 1151-1164.	7.3	22
74	Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. Clinical Nutrition, 2011, 30, 647-652.	5.0	21
75	Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B. Medicine (United States), 2015, 94, e1341.	1.0	21
76	Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma. Medicine (United States), 2015, 94, e1772.	1.0	21
77	Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3196-3203.	2.8	21
78	Positive Selection of Hepatitis Delta Antigen in Chronic Hepatitis D Patients. Journal of Virology, 2007, 81, 4438-4444.	3.4	20
79	Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. Hepatology International, 2012, 6, 753-762.	4.2	20
80	Uncompromised Treatment Efficacy in Elderly Patients With Hepatocellular Carcinoma. Medicine (United States), 2014, 93, e264.	1.0	20
81	Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver International, 2020, 40, 2522-2534.	3.9	20
82	Characteristics and outcome of patients with dual hepatitis B and Câ€essociated hepatocellular carcinoma: are they different from patients with single virus infection?. Liver International, 2009, 29, 767-773.	3.9	19
83	Prognostic Significance of Computed Tomography Scan-derived Splenic Volume in Hepatocellular Carcinoma Treated With Radiofrequency Ablation. Journal of Clinical Gastroenterology, 2012, 46, 789-795.	2.2	19
84	Risk of Hepato-Biliary Cancer After Cholecystectomy: a Nationwide Cohort Study. Journal of Gastrointestinal Surgery, 2013, 17, 345-351.	1.7	19
85	Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. Journal of the Formosan Medical Association, 2020, 119, 218-229.	1.7	19
86	CXCL9 Associated with Sustained Virological Response in Chronic Hepatitis B Patients Receiving Peginterferon Alfa-2a Therapy: A Pilot Study. PLoS ONE, 2013, 8, e76798.	2.5	18
87	Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. Annals of Hepatology, 2013, 12, 263-273.	1.5	18
88	Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. Annals of Hepatology, 2015, 14, 181-189.	1.5	18
89	Acute kidney injury predicts mortality in cirrhotic patients with gastric variceal bleeding. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1859-1866.	2.8	18
90	Ropeginterferon alfa-2b every 2Âweeks as a novel pegylated interferon for patients with chronic hepatitis B. Hepatology International, 2020, 14, 997-1008.	4.2	18

#	Article	IF	CITATIONS
91	Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma. Scientific Reports, 2020, 10, 3925.	3.3	18
92	Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. Hepatology International, 2013, 7, 645-654.	4.2	17
93	Performance Status Enhances the Selection of Treatment for Patients with Hepatocellular Carcinoma Within the Milan Criteria. Annals of Surgical Oncology, 2013, 20, 2035-2042.	1.5	17
94	A Comparison of Clinical Manifestations and Prognoses Between Patients with Hepatocellular Carcinoma and Child–Pugh Scores of 5 or 6. Medicine (United States), 2014, 93, e348.	1.0	17
95	Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 238-238.	1.7	17
96	Easy albumin–bilirubin score as a new prognostic predictor in hepatocellular carcinoma. Hepatology Research, 2021, 51, 1129-1138.	3.4	17
97	A New Tumor Burden Score and Albumin–Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma. Cancers, 2022, 14, 649.	3.7	17
98	Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study. Journal of Infectious Diseases, 2018, 218, 1075-1084.	4.0	16
99	Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. Journal of the Chinese Medical Association, 2019, 82, 2-10.	1.4	16
100	The correlation between fatty liver disease and chronic kidney disease. Journal of the Formosan Medical Association, 2020, 119, 42-50.	1.7	16
101	Fibroscan-Based Score to Predict Significant Liver Fibrosis in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. Obesity Surgery, 2020, 30, 1249-1257.	2.1	16
102	Second primary cancers in patients with hepatocellular carcinoma: a nationwide cohort study in Taiwan. Liver International, 2013, 33, 616-623.	3.9	15
103	Endoscopic ultrasonography assessment of para-esophageal varices predicts efficacy of propranolol in preventing recurrence of esophageal varices. Journal of Gastroenterology, 2015, 50, 342-349.	5.1	15
104	A Novel AURKA Mutant-Induced Early-Onset Severe Hepatocarcinogenesis Greater than Wild-Type via Activating Different Pathways in Zebrafish. Cancers, 2019, 11, 927.	3.7	15
105	An Albumin-Bilirubin (ALBI) Grade–based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 698-704.	1.3	15
106	Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C. Journal of the Formosan Medical Association, 2021, 120, 956-964.	1.7	15
107	Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines. Hepatology International, 2021, 15, 1421-1430.	4.2	15
108	Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease. Gastroenterology Research and Practice, 2017, 2017, 1-12.	1.5	14

#	Article	IF	CITATIONS
109	Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan. Journal of Microbiology, Immunology and Infection, 2021, 54, 385-395.	3.1	14
110	A New Prognostic Model Based on Albumin–Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria. Digestive Diseases and Sciences, 2020, 65, 658-667.	2.3	14
111	Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers, 2021, 13, 1729.	3.7	14
112	Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy. Journal of the Formosan Medical Association, 2021, 120, 1563-1571.	1.7	14
113	Comparison of clinical manifestations and epidemiology between acute hepatitis A and acute hepatitis E in Taiwan. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 1187-1191.	2.8	13
114	Pro-205 of large hepatitis delta antigen and Pro-62 of major hepatitis B surface antigen influence the assembly of different genotypes of hepatitis D virus. Journal of General Virology, 2010, 91, 1004-1012.	2.9	13
115	Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatology International, 2011, 5, 975-984.	4.2	13
116	The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis. European Radiology, 2017, 27, 2600-2609.	4.5	13
117	Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: A propensity score matching analysis. Journal of the Formosan Medical Association, 2020, 119, 610-620.	1.7	13
118	Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: A propensity score analysis and staging strategy. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 690-699.	2.8	12
119	Impact of etiological treatment on prognosis. Hepatology International, 2018, 12, 56-67.	4.2	12
120	High Expression of MicroRNA-196a is Associated with Progression of Hepatocellular Carcinoma in Younger Patients. Cancers, 2019, 11, 1549.	3.7	12
121	Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. Annals of Hepatology, 2015, 14, 181-9.	1.5	12
122	The safety and probable therapeutic effect of routine use of antibiotics and simultaneously treating bleeding gastric varices by using endoscopic cyanoacrylate injection and concomitant esophageal varices with banding ligation: a pilot study. Gastrointestinal Endoscopy, 2010, 71, 1141-1149.	1.0	11
123	Reactivation of hepatitis B virus after transarterial chemo-embolization for hepatocellular carcinoma in one patient with negative hepatitis B surface antigen. Journal of Hepatology, 2010, 52, 463-465.	3.7	11
124	Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1581-1588.	2.8	11
125	Hepatitis D Virus Isolates with Low Replication and Epithelial-Mesenchymal Transition-Inducing Activity Are Associated with Disease Remission. Journal of Virology, 2012, 86, 9044-9054.	3.4	11
126	A prognostic model for patients with hepatocellular carcinoma within the <scp>M</scp> ilan criteria undergoing nonâ€transplant therapies, based on 1106 patients. Alimentary Pharmacology and Therapeutics, 2012, 36, 551-559.	3.7	11

#	Article	IF	CITATIONS
127	Hepatocellular carcinoma in uremic patients: Is there evidence for an increased risk of mortality?. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 348-356.	2.8	11
128	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. Journal of the Formosan Medical Association, 2019, 118, 556-564.	1.7	11
129	Differential prognoses among male and female patients with hepatocellular carcinoma. Journal of the Chinese Medical Association, 2022, 85, 554-565.	1.4	11
130	Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: a novel role of α-fetoprotein. Liver International, 2010, 30, 1161-1168.	3.9	10
131	Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems. Digestive and Liver Disease, 2012, 44, 868-874.	0.9	10
132	Differential roles of serum hepatitis <scp>B</scp> virus <scp>DNA</scp> and hepatitis <scp>B</scp> surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1849-1858.	2.8	10
133	Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade. Cancers, 2020, 12, 1130.	3.7	10
134	Albumin–Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Digestive Diseases and Sciences, 2021, 66, 1730-1738.	2.3	10
135	Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAgâ€positive cancer patients undergoing chemotherapy. Journal of Viral Hepatitis, 2018, 25, 1599-1607.	2.0	9
136	Systemic Amyloidosis Manifesting as a Rare Cause of Hepatic Failure. Journal of the Chinese Medical Association, 2010, 73, 161-165.	1.4	8
137	Citrus reticulata peel improves patient tolerance of low-volume polyethylene glycol for colonoscopy preparation. Journal of the Chinese Medical Association, 2012, 75, 442-448.	1.4	8
138	A New Child-Turcotte-Pugh Class 0 for Patients with Hepatocellular Carcinoma: Determinants, Prognostic Impact and Ability to Improve the Current Staging Systems. PLoS ONE, 2014, 9, e99115.	2.5	8
139	The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment. Medicine (United States), 2015, 94, e1659.	1.0	8
140	Staging for hepatocellular carcinoma: An embarrassment of riches. Journal of Hepatology, 2016, 64, 535-536.	3.7	8
141	Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. Scientific Reports, 2018, 8, 15074.	3.3	8
142	The role of albumin–bilirubin grade in determining the outcomes of patients with very early-stage hepatocellular carcinoma. Journal of the Chinese Medical Association, 2021, 84, 136-143.	1.4	8
143	Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. Cancers, 2021, 13, 4325.	3.7	8
144	Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance. Cells, 2022, 11, 634.	4.1	8

#	Article	IF	CITATIONS
145	Core Antigen Expression Is Associated with Hepatic Necroinflammation in e Antigen-Negative Chronic Hepatitis B Patients with Low DNA Loads. Vaccine Journal, 2010, 17, 1048-1053.	3.1	7
146	Hepatocellular Carcinoma With Presentation of Budd-Chiari Syndrome. Journal of the Chinese Medical Association, 2010, 73, 93-96.	1.4	7
147	Clinical efficacy of Rong-Yang-Jyh-Gan-Tang on patients with chronic hepatitis C: A double-blinded randomized placebo-controlled crossover study. Journal of Ethnopharmacology, 2017, 196, 1-8.	4.1	7
148	Esophageal varices are not predictive of patient prognosis after surgical resection of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2018, 30, 1368-1377.	1.6	7
149	Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan. Journal of the Chinese Medical Association, 2019, 82, 693-698.	1.4	7
150	A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices. Scientific Reports, 2020, 10, 17259.	3.3	7
151	Statin inhibits large hepatitis delta antigen-Smad3 -twist-mediated epithelial-to-mesenchymal transition and hepatitis D virus secretion. Journal of Biomedical Science, 2020, 27, 65.	7.0	7
152	Liver stiffness measured by acoustic radiation force impulse elastography predicted prognoses of hepatocellular carcinoma after radiofrequency ablation. Scientific Reports, 2020, 10, 2006.	3.3	7
153	Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis. Journal of the Chinese Medical Association, 2022, 85, 30-41.	1.4	7
154	Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. Annals of Hepatology, 2013, 12, 263-73.	1.5	7
155	Hepatic Splenosis Diagnosed by Spleen Scintigraphy. American Journal of Gastroenterology, 2008, 103, 1842-1844.	0.4	6
156	Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. PLoS ONE, 2017, 12, e0188552.	2.5	6
157	Less barium enema, more colonoscopy. Journal of the Chinese Medical Association, 2019, 82, 312-317.	1.4	5
158	Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus–coinfected patients treated by all-oral direct-acting antivirals. Journal of the Chinese Medical Association, 2021, 84, 465-471.	1.4	5
159	Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients. PLoS ONE, 2015, 10, e0137852.	2.5	5
160	Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin–bilirubin grade. International Journal of Clinical Oncology, 2022, 27, 739-748.	2.2	5
161	Comparison of prognoses between cirrhotic and noncirrhotic patients with hepatocellular carcinoma and esophageal varices undergoing surgical resection. Journal of the Chinese Medical Association, 2022, 85, 679-686.	1.4	5
162	Surgical resection could provide better outcomes for patients with hepatocellular carcinoma and tumor rupture. Scientific Reports, 2022, 12, 8343.	3.3	5

#	Article	IF	CITATIONS
163	Generation of cytotoxicity against hepatitis delta virus genotypes and quasispecies by epitope modification. Journal of Hepatology, 2009, 50, 779-788.	3.7	4
164	Healthy Chinese with benign pancreatic hyperenzymemia. Journal of the Chinese Medical Association, 2015, 78, 623-626.	1.4	4
165	Low air temperature increases the risk of oesophageal variceal bleeding: a population and hospitalâ€based caseâ€crossover study in Taiwan. Liver International, 2016, 36, 856-864.	3.9	4
166	Highly effective treatment response and well tolerability by all oral direct acting antivirals for chronic hepatitis C patients post organ transplantation. Journal of the Chinese Medical Association, 2020, 83, 18-24.	1.4	4
167	Nucleos(t)ide analogue continuous therapy associated with reduced adverse outcomes of chronic hepatitis B. Journal of the Chinese Medical Association, 2020, 83, 125-133.	1.4	4
168	Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAg. American Journal of Cancer Research, 2021, 11, 3711-3725.	1.4	4
169	Cryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. Scandinavian Journal of Gastroenterology, 2023, 58, 61-69.	1.5	4
170	Hepatocellular Carcinoma With Invasion Into Right Atrium. Clinical Gastroenterology and Hepatology, 2008, 6, e39-e40.	4.4	3
171	Gastrointestinal bleeding because of hookworm infection diagnosed by capsule endoscopy. European Journal of Gastroenterology and Hepatology, 2009, 21, 1219.	1.6	3
172	Vomiting and diarrhea in a woman with systemic lupus erythematosus. Journal of the Chinese Medical Association, 2015, 78, 133-135.	1.4	3
173	Outcomes of resection surgery for hepatocellular carcinoma: Does size matter?. Journal of the Chinese Medical Association, 2018, 81, 89-91.	1.4	3
174	A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin. Journal of the Chinese Medical Association, 2019, 82, 186-190.	1.4	3
175	Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B. Journal of the Formosan Medical Association, 2020, 120, 1676-1685.	1.7	3
176	Sofosbuvir-based antiviral therapy provided highly treatment efficacy, safety, and good tolerability for Taiwanese chronic hepatitis C patients with decompensated cirrhosis. Journal of the Chinese Medical Association, 2022, 85, 152-159.	1.4	3
177	Hepatocellular Carcinoma With Sternal Metastasis. Clinical Gastroenterology and Hepatology, 2011, 9, e46-e47.	4.4	2
178	Establishing a risk scoring system for predicting erosive esophagitis. Advances in Digestive Medicine, 2016, 3, 95-100.	0.2	2
179	Interval to vascularization development in cirrhotic precursor nodules in patients with hepatitis B and C virus co-infections. PLoS ONE, 2017, 12, e0178841.	2.5	2
180	Determination of the predictive factors for significant liver fibrosis assessed through transient elastography. Advances in Digestive Medicine, 2019, 6, 5-14.	0.2	2

#	Article	IF	CITATIONS
181	Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2020, 32, 365-372.	1.6	2
182	Toward a new landscape for the mechanism of immunosuppression in hepatocellular carcinoma. Hepatology International, 2021, 15, 287-289.	4.2	2
183	Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response. Journal of the Chinese Medical Association, 2021, 84, 472-477.	1.4	2
184	A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 19-27.	1.1	2
185	Successful Radiofrequency Ablation Therapy for Hepatocellular Carcinoma in a Male Patient with Early Stage Primary Biliary Cirrhosis and Positive Serum Hepatitis B Core Antibody. Journal of the Chinese Medical Association, 2008, 71, 40-44.	1.4	1
186	Autoimmune hepatitis combined with multiple viral infections. European Journal of Gastroenterology and Hepatology, 2008, 20, 1122-1123.	1.6	1
187	Wandering abdominal pain due to a floating gallbladder. Digestive and Liver Disease, 2013, 45, e13.	0.9	1
188	Letter: the role of directâ€acting antiâ€virals in determining the risk of hepatocellular carcinoma development in patients with hepatitis C virusâ€induced cirrhosis. Alimentary Pharmacology and Therapeutics, 2018, 47, 1230-1231.	3.7	1
189	Hepatitis B virus and glomerulonephritis: Two silent killers. Advances in Digestive Medicine, 2018, 5, 111-112.	0.2	1
190	Proton pump inhibitors and risk of hepatocellular carcinoma: a population-based study. Journal of Hepatology, 2018, 68, S429.	3.7	1
191	Schistosomiasis infectionâ€related cholangiocarcinoma. Advances in Digestive Medicine, 2019, 6, 132-133.	0.2	1
192	FRI-185-Virological and immunological predictors of long-term ouctomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B. Journal of Hepatology, 2019, 70, e471.	3.7	1
193	ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy. Journal of Gastrointestinal Oncology, 2021, 12, 722-734.	1.4	1
194	Right inguinal metastasis from hepatocellular carcinoma. Advances in Digestive Medicine, 0, , .	0.2	1
195	IDDF2021-ABS-0071â€Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. , 2021, , .		1
196	Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210994.	3.2	1
197	Letter: pyogenic liver abscess is a red flag sign of hepatocellular carcinoma – authors' reply. Alimentary Pharmacology and Therapeutics, 2012, 36, 906-907.	3.7	0
198	Letter: pyogenic liver abscess and colorectal cancer – authors' reply. Alimentary Pharmacology and Therapeutics, 2013, 37, 165-166.	3.7	0

#	Article	IF	CITATIONS
199	The Use of Ultrasound-guided Radiofrequency Ablation Therapy for Small Hepatocellular Carcinomas. Journal of Medical Ultrasound, 2014, 22, 7-8.	0.4	0
200	Uterine cervical squamous cell carcinoma with duodenal metastasis causes obstructive jaundice. Advances in Digestive Medicine, 2017, 4, 76-79.	0.2	0
201	The effect of primary prophylaxis therapy for large esophageal varices in patients with hepatocellular carcinoma. Journal of Hepatology, 2018, 68, S713.	3.7	0
202	Propranolol treatment associated with better survival and reduced sepsis in cirrhotic patients with hepatic encephalopathy. Journal of Hepatology, 2018, 68, S711-S712.	3.7	0
203	SAT-462-Current non-invasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e836-e837.	3.7	0
204	SAT-463-Albumin-bilirubin grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e837-e838.	3.7	0
205	Keep scalpel sheathed: A metastatic invasive ductal carcinoma mimics primary linitis plastica. Advances in Digestive Medicine, 2019, 6, 36-39.	0.2	0
206	Reply. Hepatology, 2019, 70, 440-441.	7.3	0
207	Towards a more comprehensive evaluation of liver fibrosis in patients with chronic hepatitis C. Journal of the Chinese Medical Association, 2019, 82, 807-808.	1.4	0
208	Valproic acid and hydralazine-modulated gemcitabine and cisplatin followed by doxorubicin in advanced hepatocellular carcinoma: A phase II study Journal of Clinical Oncology, 2015, 33, e15119-e15119.	1.6	0
209	Zafirlukast-induced acute hepatitis. Zhonghua Yi Xue Za Zhi = Chinese Medical Journal; Free China Ed, 2002, 65, 553-6.	0.0	0
210	Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resection. American Journal of Cancer Research, 2021, 11, 5526-5542.	1.4	0
211	Splenic artery pseudoaneurysm as a fatal complication of acute pancreatitis. Advances in Digestive Medicine, 0, , .	0.2	0

Liver tumor encapsulating the gallbladder. , 2022, , .